Business Context and Reporting Period
Amplitude Healthcare Acquisition Corporation, a special purpose acquisition company, filed this Form 8-K on May 6, 2021, reporting events occurring on May 5, 2021. The filing concerns its proposed business combination with Jasper Therapeutics, Inc., a biotechnology company. Following completion, the combined company is expected to be renamed Jasper Therapeutics, Inc.
Transaction Terms and Key Financial Metrics
- Amplitude, its wholly owned subsidiary Ample Merger Sub, Inc., and Jasper entered into a Business Combination Agreement on May 5, 2021.
- Merger Sub will merge with Jasper, with Jasper surviving as a wholly owned subsidiary of Amplitude at closing.
- Jasper’s equity value for purposes of the transaction is $275.0 million.
- Jasper common and preferred stock will convert into shares of the combined company; Jasper options and restricted stock awards will be converted into comparable awards.
- The parties entered into PIPE subscription agreements for 10,000,000 shares at $10.00 per share, representing aggregate gross proceeds of $100.0 million. The PIPE financing is contingent on completion of the business combination and will initially be issued in an unregistered offering.
- A minimum cash condition requires at least $130.0 million from available trust-account proceeds after redemptions plus PIPE proceeds at closing.
- The filing does not provide revenue, net income, cash flow, operating margin, debt, cash balance, or other historical financial statement metrics for Jasper or Amplitude.
Material Changes Versus the Prior Comparable Period
This is a transaction announcement rather than a periodic financial report. The filing does not present comparative operating results or quantify changes from a prior period. The material development is the execution of the proposed merger agreement and associated $100.0 million PIPE financing.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Closing is expected in the third quarter of 2021, subject to stockholder approvals and other customary conditions.
- Required conditions include regulatory clearance or expiration of the Hart-Scott-Rodino waiting period, effectiveness of the registration statement/proxy statement, Nasdaq listing approval, approval by Amplitude and Jasper stockholders, and minimum post-transaction net tangible assets of $5,000,001 for Amplitude.
- The transaction may be terminated under specified circumstances, including uncured breaches, failure to close by November 30, 2021, governmental prohibition, or failure to obtain the required Amplitude stockholder vote.
- The Sponsor agreed to support the transaction, vote its shares in favor, accept transfer restrictions, place specified shares into earnout arrangements, and forfeit private placement warrants subject to the support agreement.
- Fifty percent of the Sponsor earnout shares may be released if the combined company’s VWAP reaches $15.00, and the remaining 50% if the VWAP reaches $18.00, subject to specified trading-period requirements during the three years after closing.
- Certain Jasper stockholders agreed to support and vote for the transaction and not transfer their Jasper shares before closing.
- The contemplated registration rights agreement includes a 180-day lock-up for specified Sponsor and Jasper stockholder shares, with an exception for shares acquired in the PIPE financing.
- Key risks include stockholder redemptions reducing trust-account proceeds, failure of the PIPE financing, failure to satisfy the minimum cash condition, inability to obtain approvals or Nasdaq listing, transaction termination, litigation, integration difficulties, disruption to operations, and failure to realize expected benefits.
Investor Verification Items
- Verify the final proxy statement, Form S-4, and definitive transaction documents for the final exchange ratio, capitalization, ownership percentages, dilution, and redemption effects.
- Confirm the amount of trust-account cash remaining after redemptions and whether the $130.0 million minimum cash condition is satisfied.
- Confirm closing approval by both stockholder groups, regulatory clearance, Nasdaq listing approval, and the actual closing date.
- Review Jasper’s historical financial statements, cash-burn rate, debt and liquidity position, clinical pipeline, and funding requirements, none of which are provided in this filing.
- Review the final PIPE terms, registration rights, sponsor earnout provisions, warrant treatment, and applicable lock-up restrictions.